EDAN(SZ:300206)2022-03-23 16:00Financial Performance - In 2021, the company achieved a net profit attributable to shareholders of 23.14 million yuan, a decrease of 64.57% year-on-year, primarily due to a nearly 60% decline in revenue from monitoring products as the market returned to normal after the pandemic surge in 2020[11]. - The company's operating revenue for 2021 was ¥1,636,411,042.84, a decrease of 29.42% compared to ¥2,318,604,231.57 in 2020[29]. - The net profit attributable to shareholders for 2021 was ¥231,436,439.33, down 64.57% from ¥653,153,458.75 in the previous year[29]. - The net profit after deducting non-recurring gains and losses was ¥191,466,158.24, a decline of 68.64% compared to ¥610,610,245.12 in 2020[29]. - The net cash flow from operating activities was ¥237,283,290.14, representing a decrease of 65.59% from ¥689,500,602.06 in the previous year[29]. - The total assets at the end of 2021 were ¥2,048,108,342.70, a decrease of 9.34% from ¥2,259,048,448.10 at the end of 2020[29]. - The net assets attributable to shareholders at the end of 2021 were ¥1,732,885,929.31, down 4.31% from ¥1,810,913,371.49 at the end of 2020[29]. - The basic earnings per share for 2021 were ¥0.3990, a decrease of 64.46% from ¥1.1228 in 2020[29]. - The weighted average return on equity for 2021 was 13.19%, down 28.48% from 41.67% in the previous year[29]. - The company reported a net profit of -¥19,377,114.29 in Q4 2021, contrasting with positive profits in the first three quarters[31]. Market Position and Growth - The medical device industry is experiencing rapid growth, driven by increasing health demands, with the domestic market expected to expand further due to favorable government policies and an aging population[14]. - The company maintains a strong competitive advantage in the medical diagnostic equipment market, with its patient monitoring, maternal and child health, and electrocardiogram diagnosis series ranking among the top domestic manufacturers[15]. - The company has established itself as a leading provider in the domestic market for patient monitoring, maternal and child health, and ECG diagnosis[46]. - The company exports its products to over 170 countries and regions worldwide, showcasing its global market presence[46]. - The company aims to enhance its core competitiveness in the medical device sector through innovation and technology development, focusing on high-end, branded, and international products[42]. Research and Development - The company has maintained a high R&D investment of CNY 252.25 million, representing a 15.69% increase year-on-year, accounting for 15.42% of operating revenue[85]. - The company holds a total of 943 valid patents, including 403 invention patents, with 95 new patents granted during the reporting period[85]. - The company is committed to increasing investment in product R&D to maintain its leading position in the medical diagnostic equipment industry[193]. - The company is actively pursuing market expansion through the development of innovative medical devices and diagnostic solutions[136]. - The company is focused on market expansion, particularly in the cardiovascular and infectious disease sectors, to capture a larger share of the healthcare market[145]. Product Development and Innovation - The company has introduced innovative products such as the i15 blood gas biochemical analyzer and m16 and m36X magnetic immune analyzers, which are at the international leading level[15]. - The company plans to launch self-developed anesthesia and muscle relaxant modules in 2022, enhancing its competitive advantage in critical care monitoring[50]. - The company has developed industry-leading ECG, blood pressure, blood oxygen, and gas technology and algorithms, facilitating remote and bedside monitoring solutions[50]. - The company is currently in the registration phase for several medical devices, including a digital ECG machine and patient monitoring systems[134]. - The company has launched several strategic new products in 2021, including the SE-1202 ECG machine and Acclarix LX9 Super ultrasound system[94][96]. Strategic Goals and Future Outlook - The company has set a strategic goal of achieving over 5 billion yuan in revenue, focusing on internal capabilities and core competitiveness[5]. - The company plans to enhance customer orientation, efficient collaboration, and a pursuit of excellence as its annual themes for 2022[6]. - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming for a total revenue of 1.875 billion RMB[151]. - The company aims to enhance its online sales channels, targeting a 50% increase in e-commerce revenue by the end of 2022[148]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[147]. Risk Management - The company emphasizes the importance of risk management, including quality control, management risks, and market competition for new products[16]. - The company faces risks in new product development due to long R&D cycles and significant investment, with potential challenges in product registration and market competition[193]. - The company is enhancing its foreign exchange risk management by monitoring political and economic conditions in key countries and adjusting the ratio of domestic and foreign sales based on exchange rate fluctuations[192]. Operational Efficiency - The company aims to improve internal management efficiency and strengthen internal control systems to mitigate operational risks[184]. - The company is committed to quality control in its testing kits, ensuring reliability and accuracy in diagnostic results[145]. - The company plans to maintain continuous investment in R&D, focusing on diversified new product development and upgrading existing products to meet clinical needs[181].